Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.
|
31693627 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Learning objectives of the present case-based review are as follows: (I.) the theranostic concept for the treatment of NET and PC will be briefly introduced, (II.) the most common pitfalls on PSMA- and SSTR-targeted PET/CT will be identified, (III.) the novel framework system for theranostic radiotracers (MI-RADS) will be explained, applied to complex clinical cases and recent studies in the field will be highlighted.
|
31331016 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, considerable efforts have been made to investigate the mechanism by which somatostatin (SST) and somatostatin receptors (SSTRs) influence PC growth and progression.
|
30828298 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.
|
31689280 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both prostate-specific membrane antigen (PSMA)- and somatostatin receptor (SSTR)-targeted positron emission tomography (PET)-based imaging agents for prostate carcinoma and neuroendocrine tumors, respectively, are seeing rapidly expanding use.
|
30109562 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
|
28905400 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, we demonstrate that sst5TMD4 is overexpressed in PCa, especially in those patients with a worse prognosis, and plays an important pathophysiologic role in PCa, which suggesting its potential as a biomarker and/or therapeutic target.-Hormaechea-Agulla, D., Jiménez-Vacas, J. M., Gómez-Gómez, E., L.-López, F., Carrasco-Valiente, J., Valero-Rosa, J., Moreno, M. M., Sánchez-Sánchez, R., Ortega-Salas, R., Gracia-Navarro, F., Culler, M. D., Ibáñez-Costa, A., Gahete, M. D., Requena, M. J., Castaño, J. P., Luque, R. M. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
|
28705809 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin (SST) and SST receptors (SS1R, SS2R, SS3R, SS4R and SS5R) appear to play a significant role in the progression of human prostate cancer (PCa), which is associated with heterogeneity of SSRs expression and specific cell localization as we already demonstrated in the LNCaP cell line, an in vitro model of human androgen-dependent PCa.
|
24211300 |
2014 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.
|
25010045 |
2014 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The enhanced XAF1 expression by somatostatin indicates a promising strategy for prostate cancer therapy.
|
21143993 |
2010 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study investigated the effects of lanreotide and new mono- and bi-specific SRIF agonists on proliferation, ligand-driven SRIF receptor (sst) dimerization and secretory pattern of the IGF system in LNCaP cells, a model of androgen-dependent PCa.LNCaP expressed all sst(s), but sst(4).
|
19932151 |
2010 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No clear association between prostate cancer risk and genetic variation of the SST and SSTR1-5 genes was identified.
|
19423539 |
2009 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using the reverse transcriptase polymerase chain reaction (RT-PCR), we found the SSTR subtypes 1-3 in stromal cells and in prostate cancer cell lines LNCaP, PC-3 and DU 145.
|
12474541 |
2002 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To shed more light on the mechanisms involved, the effects of JV-1-38 on PC-3 human prostate cancer were compared with those of somatostatin analog RC-160 in vivo and in vitro.
|
12111694 |
2002 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer.
|
9253335 |
1997 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated somatostatin receptors (SSTRs) in surgical specimens of prostate cancer and benign prostate hyperplasia (BPH), a normal immortalized epithelial cell line (PNT1), epithelial cancer cell lines, and stromal cells in short-term culture derived from normal and BPH biopsies.
|
8674827 |
1995 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptors in human prostate and prostate cancer.
|
7673428 |
1995 |